BioPivot’s most consequential enrollment question is not which monthly price looks lowest. It is what happens after you submit your intake and authorize payment. The homepage advertises a first review at no charge and “$0 if you’re not approved,” while the cancellation policy says an applicant declined after clinical review receives a refund minus a $59 doctor consultation fee. For someone comparing the financial consequences of applying, those are materially different promises. The consulted documents do not resolve which one controls a particular purchase.
BioPivot, LLC presents itself as a U.S. telehealth technology platform connecting patients with independent clinicians and compounding pharmacies. It lists compounded semaglutide, compounded tirzepatide and options called microdosing, with monthly and quarterly prices. This documentary review examines the public pages consulted October 19, 2026, emphasizing enrollment obligations, payment authorization, cancellation and responsibility for care. The offering is described in considerable detail, but the relationship between a three-month membership, monthly billing and quarterly purchasing needs written clarification before payment.
At a glance
- First-review price conflict
- The homepage advertises $0 if not approved; the cancellation policy retains a $59 consultation fee after a clinician declines treatment.
- Published treatment prices
- Compounded semaglutide Starter is $185 monthly or $400 quarterly; compounded tirzepatide Starter is $242 monthly or $590 quarterly.
- Membership and recurring billing
- The cancellation policy describes a three-month membership; the terms authorize recurring monthly orders to be charged immediately and every 30 days.
- Renewal cutoff
- The terms require turning off auto-refill at least 48 hours before the applicable monthly processing date.Sources: [7]
The first financial decision happens before approval
The homepage’s invitation is straightforward: new patients receive their first review at no charge, with nothing owed if they are not approved. Elsewhere, the cancellation policy establishes a different sequence. A full refund of any paid membership or intake fee is available before a provider reviews the intake and clinical evaluation begins. Once a provider reviews the application and decides the person is not a candidate, that policy says BioPivot keeps $59 and refunds the remainder of the membership payment.
That distinction makes the start of clinical review a financial boundary, even if no medication is prescribed. The documents do not explain whether the homepage offer overrides the policy, requires a particular promotion or applies only to selected enrollment routes. Nor do they establish a way to know precisely when the review begins. A prospective customer should request confirmation of the amount authorized at checkout and the amount retained if treatment is declined, rather than assuming the prominent advertising resolves the conflict.
For this provider, a useful pre-enrollment terms check starts with a narrow written question: does the $59 consultation retention apply to this purchase despite the homepage’s $0 statement? Keep the answer with the checkout disclosures. That is more actionable than a general assurance that the consultation is free, because the policy distinguishes cancellation before review from rejection after review. Selecting a program or completing an intake does not guarantee a prescription.
Monthly prices do not settle the membership commitment
BioPivot publishes concrete prices rather than requiring every applicant to obtain a private quote. Its semaglutide and tirzepatide pages divide conventional programs into Starter, Continuation and Maintenance tiers, while a separate page lists microdosing options. The table preserves the monthly and quarterly alternatives as advertised. These are compounded products; the consulted descriptions do not expressly establish their administration route, concentration, presentation or quantity supplied. A quarterly price therefore should not be treated as proof of a particular medication supply.
The homepage also advertises plans from $149 per month, confirmed after provider review, without identifying which product qualifies for that minimum. Treatment pages advertise 20% off a first order with BIOPIVOT20. That is an introductory discount, not a documented reduction on later orders. The listed plan prices should remain the starting point for comparison; neither the unidentified $149 offer nor the promotion establishes what a specific applicant will pay after review.
More importantly, the cancellation policy describes a three-month telehealth membership, while the terms authorize recurring monthly orders to be charged immediately and every 30 days until canceled. Quarterly prepayment conditions and the relationship between these arrangements are not explained. A monthly price and commitment comparison should distinguish the selected billing alternative, any minimum obligation and the renewal date. Thirty-day billing is not identical to billing once per calendar month.
| Program | Monthly option | Quarterly option |
|---|---|---|
| Semaglutide: Starter / Continuation / Maintenance | $185 / $218 / $225 | $400 / $490 / $518 |
| Tirzepatide: Starter / Continuation / Maintenance | $242 / $315 / $350 | $590 / $780 / $900 |
| Semaglutide Microdosing | $168 | $370 |
| Tirzepatide Microdosing | $220 | $528 |
What the bundled payment covers—and what remains open
The terms describe a single bundled subscription price covering three components: the pharmacy’s prescription-drug fee, the medical group’s professional-service fee and BioPivot’s platform-access fee. The cancellation policy says the three-month membership includes medical review, provider support, messaging and treatment fulfillment if approved. Treatment pages add compounded medication prepared by partner pharmacies, direct physician messaging through a secure portal and structured check-ins. Those descriptions establish the intended package, but not the frequency or duration of every included service.
Delivery is advertised in temperature-controlled, unmarked packaging, with medication shipped on a structured cadence. The consulted documentation does not specify preparation time, dispatch time, arrival time, carrier or exact supply intervals. It also does not settle whether administration materials, mandatory testing, additional consultations or shipping charges could be separate. The practical question is not simply whether support and fulfillment are included, but whether the complete checkout amount covers the particular services and supplies required for the approved plan.
Laboratory testing deserves separate attention. BioPivot advertises baseline bloodwork and monitoring when a licensed provider considers them appropriate, and lists a Comprehensive Panel at $228.30. The documentation does not establish whether that panel is included in any treatment membership. A Tasso home capillary-collection kit is marked coming soon, without a price. Insurance acceptance, insurer billing, out-of-network reimbursement and HSA/FSA payment are also unconfirmed; silence on these points is not evidence of either acceptance or exclusion.
Cancellation requires attention to both renewal and order status
BioPivot provides three cancellation routes: Account > Subscription > Cancel Membership, email to info@biopivot.co with the account holder’s full name and registered email, or a call to 520-210-4673 during business hours. The policy says requests are processed within one business day, with remaining benefits continuing through the end of the three-month membership period. However, continued access does not itself establish a refund, and the three-month wording does not explain the total payment obligation for someone who selected monthly pricing.
The terms add a specific renewal rule: turn off auto-refill in the portal at least 48 hours before the monthly processing date. They also promise an electronic notice five to seven days before a scheduled recurring transaction and a receipt after a successful charge. Read alongside the policy’s cancellation language, this creates two tasks: stopping future billing before its cutoff and determining whether an existing prescription order can still be stopped. The documents do not state which provision prevails if their application conflicts.
Order status matters because issuing a prescription, transmitting it to a pharmacy and shipping medication are separate events. Before shipment, the policy describes a partial membership refund minus $59, but warns that cancellation cannot be guaranteed after pharmacy transmission. After shipment, compounded-medication sales are final except for specified delivery or pharmacy problems. A useful cancellation timing checklist should record the next processing date, cancellation submission and pharmacy status—not merely the date the customer decided to leave.
Refund exceptions have their own deadlines
The refund policy is most permissive before clinical evaluation begins and becomes more restrictive as the order advances. After a prescription but before shipment, it describes a partial refund less the $59 consultation fee, without fully explaining how that partial amount is calculated across monthly and quarterly purchases. After shipment, the stated exceptions concern pharmacy error or damaged or incorrect delivery. These boundaries make cancellation and refund separate questions: ending a subscription does not reverse a medication sale already completed.
For damaged packages or the wrong medication or dosage, BioPivot requires contact at info@biopivot.co within seven days of delivery, including photographs of the packaging and product. It says it will coordinate a replacement at no cost. For an order confirmed by tracking as lost and not delivered, contact is required within 14 days of the expected delivery date, with reshipment at no additional charge. Those provisions promise specific remedies; they should not be expanded into a general satisfaction guarantee.
Approved refunds are processed to the original payment method within five to ten business days, and the policy allows another three to five business days for the bank or card issuer to display the credit. Processing therefore is not the same as money reaching the account. Separately, FDA advises not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. BioPivot’s temperature-controlled packaging claim does not replace that delivery-safety guidance.
Who actually owes the clinical and pharmacy services?
BioPivot’s terms identify BioPivot, LLC as the website owner and operator but describe it solely as a technology platform. The company says it does not practice medicine, provide clinical care, prepare or dispense medication, or control independent professionals’ judgment. The homepage names Elite Care Health for clinical care and Rx Ave Health for pharmacy and prescription fulfillment. This division is central to understanding the purchase: one bundled payment does not mean one organization performs every service.
The homepage lists Elite Care Health at mayur@elite-care.health and 810-348-3003, and Rx Ave Health at info@rxave.health and (833) 360-4276. BioPivot says it connects patients with independent U.S. board-certified clinical providers and state-licensed compounding pharmacies; its policy describes custom preparations from licensed 503A pharmacies. These are provider statements, not independently verified credentials. The consulted documentation does not identify which specific compounding pharmacy would prepare an individual order or establish the qualifications of the clinician assigned to it.
The terms also condition prescription purchases on accepting fulfillment through the platform’s pharmacies, using a contractual waiver of pharmacy choice. A customer wanting to fill elsewhere should resolve that restriction before buying rather than assuming the prescription can be transferred. The terms further warn that prescription products will not be dispensed in child-resistant containers. A map of provider responsibilities is useful here: billing assistance, prescribing decisions, preparation and dispensing questions may require different contacts.
The intake is a review process, not a treatment guarantee
BioPivot describes a brief online intake reviewed by the care team before a conversation with a physician. A licensed medical provider may request more information, laboratory work or a consultation before making a treatment decision. The homepage says most applicants hear back within 48 hours, which is a review-response statement—not a dispensing or delivery deadline. Its BMI calculator is expressly a starting point, with eligibility confirmed during assessment rather than established by the calculator or by selecting a program.
The terms require customers to be at least 18, or the local age of majority if higher, and physically in the same state as their account’s shipping address when consulting a provider. Potential availability in all 50 states is qualified by clinical appropriateness and applicable law. Treatment pages also state exclusions for personal or family history of medullary thyroid carcinoma or MEN 2, pregnancy and breastfeeding. These are BioPivot’s published restrictions, not a complete individualized eligibility assessment.
The product distinction also matters. BioPivot acknowledges that its compounded medications are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Lack of approval alone does not establish clinical inequivalence, but neither BioPivot’s conventional plans nor its microdosing labels establish provider-specific outcomes. The consulted descriptions do not supply enough product detail to infer route, formulation or clinical performance from the program name.
Support access and privacy need a closer reading
BioPivot’s contact page publishes info@biopivot.co and 520-210-4673, with clinical hours Monday through Friday, 9 a.m. to 5 p.m. The displayed hours do not identify a time zone. Its contact form promises a team response within 24 hours, separate from the homepage’s statement that most applicants hear back within 48 hours. Neither promise establishes round-the-clock clinical availability, and the consulted documentation does not confirm Spanish-language service, interpreters or response times for every portal message.
The privacy documents also require reading together. The general policy says BioPivot does not sell, rent or trade personal information. The California notice says certain disclosures to support advertising may count as a sale or sharing under California law, and specifies its priority for California consumers. That distinction should not be flattened into either an absolute no-sharing assurance or an unsupported claim that medical records are sold. It is a reason to examine the applicable advertising and privacy choices.
Finally, the terms’ HIPAA language refers to Pura Labs LLC despite identifying BioPivot, LLC as the platform operator. The consulted text does not explain the relationship. This is a documentary inconsistency, not enough to reach a legal conclusion about compliance or corporate ownership. Before enrolling, customers can ask which entity receives health information, which organization handles privacy requests and which policy governs their account. Clear answers would strengthen the otherwise incomplete allocation of service and data responsibilities.
Questions & answers
Will BioPivot charge me if I am not approved?
The documents conflict. The homepage advertises $0 if not approved, while the cancellation policy says a provider’s rejection triggers a refund minus a $59 doctor consultation fee. Before review starts, that policy permits a full refund of paid membership or intake fees. Ask which provision applies to your enrollment and obtain the answer before authorizing payment.
Does choosing a monthly price mean I can leave after one month?
That is not established. Monthly and quarterly prices appear on treatment pages, the policy describes a three-month membership, and recurring monthly orders are charged immediately and every 30 days. The documents do not reconcile those arrangements or clearly specify quarterly prepayment conditions. Request the total obligation and cancellation consequences for the exact option selected.
How do I stop a BioPivot renewal?
The terms say to turn off auto-refill in the portal at least 48 hours before the monthly processing date. The cancellation policy also accepts account cancellation, email and telephone requests and says processing takes one business day. Confirm that both future billing and any pending pharmacy order have been addressed; cancellation of one does not establish cancellation of the other.
Can I use my preferred pharmacy?
BioPivot’s terms require prescription purchases to use the platform’s pharmacy channel and include a waiver of pharmacy choice. The homepage identifies Rx Ave Health for pharmacy and fulfillment, but the consulted documentation does not identify the specific preparing pharmacy for each patient. Someone who wants outside fulfillment should clarify that restriction before purchasing.
Are laboratory tests included in the subscription?
The public documentation does not settle that question. BioPivot advertises testing when clinically appropriate and separately lists a Comprehensive Panel for $228.30, without explaining whether a membership includes it. A provider may request laboratory work before deciding on treatment. Ask which tests are required, who performs them and whether their charges are inside or outside your quoted package.
What happens if my delivery is damaged, incorrect or missing?
Report damage or an incorrect medication or dosage within seven days of delivery, with packaging and product photographs. For tracking-confirmed loss, contact BioPivot within 14 days of the expected delivery date. The policy promises replacement or reshipment without additional charge in those circumstances. For an injectable arriving warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy.
Our assessment
BioPivot provides useful published prices, identifiable clinical and fulfillment contacts, multiple cancellation channels and specific delivery-problem deadlines. Its bundled-service description also gives prospective customers more substance than a headline price alone. The principal weakness is that several documents describe the financial relationship differently: a free first review versus a retained $59 fee, monthly and quarterly options versus a three-month membership, and general cancellation access versus a 48-hour renewal cutoff. These differences do not establish misconduct, but they prevent a confident reading of the purchase obligation from the public pages alone. A practical next step is to obtain written confirmation of the initial charge, rejection fee, selected billing interval, total commitment, next renewal date and treatment-order cancellation boundary. Contract clarity would improve the enrollment decision; it would not independently verify pharmacy credentials, establish clinical outcomes or make compounded products FDA approved.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.